EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.

Guideline ID: 3519 Published: 2024 Jan 2

European Alliance of Associations for Rheumatology (EULAR)

Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2;83(1):30-47. [226 references] PubMed

View Original Guideline

Overview

Guideline Objective

To develop EULAR recommendations for the diagnosis and treatment of adult patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)

Patient Population

Adult patients with AAV

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Diagnostic evaluation, including biopsy and antigen-specific assay testing
- Guidance on use of pharmacotherapy for induction of remission and remission maintenance in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA)
- Role of plasma exchange to treat alveolar hemorrhage or to induce remission
- Considerations for clinical assessment to inform decisions in treatment
- Use of prophylaxis in patients receiving immunosuppressive therapy

Note: Refer to the original guideline for full recommendation statements.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis (AAV): Part 1 - Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis; 2023 Jul.
  - Supplementary Materials.
  - Evidence Tables.
- Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis (AAV): Part

2 - Treatment of Eosinophilic Granulomatosis with Polyangiitis and Diagnosis and General Management of AAV; 2023 Jun.

- Supplement 1.
- Supplement 2.
- Evidence Tables.

Implementation Tools

- The Original Guideline includes the following:
  - Figure 1. The 2022 EULAR Algorithm for Treatment of Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) (p. 35)
  - Figure 3. The 2022 EULAR Algorithm for Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) (p. 39)

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

TRUST Scorecard

Composition of Guideline Development Group (GDG)

Multidisciplinary GDG Members	**Yes**
Methodologist Involvement	**Yes**
Incorporation of Patient and Public Perspective	★★★★☆

Systematic Review of Evidence

Literature Search	★★★★★
Study Selection	★★★★★
Evidence Synthesis	★★★★★

Foundations for Recommendations

Strength of Evidence Grade	★★★☆☆
Description of Benefits and Harms of Recommendations	★★★★☆
Summary of Evidence Supporting Recommendations	★★★★★
Strength of Recommendations Rating	★★★☆☆
Clear Articulation of Recommendations	★★★★☆

Funding Source — **Yes**

Disclosure and Management of Financial Conflicts of Interests — ★★★☆☆

External Review — ★★★☆☆

Updating — ★★☆☆☆

Copyright © 2025 ECRI